Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer

Tyrosine kinase inhibitors such as erlotinib are commonly used as a therapeutic agent against cancer due to its relatively low side-effect profile and, at times, greater efficacy. However, erlotinib resistance (ER) in non-small cell lung cancer is being recognized as a major problem. Therefore, unde...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2012-10, Vol.7 (10), p.e48532
Hauptverfasser:	Lee, Jasmine G, Wu, Reen
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma Apoptosis Apoptosis - drug effects Apoptosis - genetics Autophagy Autophagy - drug effects Autophagy - genetics Autophagy-Related Proteins Binding sites Biology Cancer Cancer research Cancer therapies Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - metabolism Cell cycle Cell death Cell Line, Tumor Cell survival Chemical compounds Chemotherapy Cisplatin Cisplatin - pharmacology Cloning Disease Drug dosages Drug Resistance, Neoplasm - genetics Epidermal growth factor Epithelial Cells Erlotinib Erlotinib Hydrochloride Health aspects Homeostasis Humans Inhibitor drugs Inhibitory Concentration 50 Internal medicine Kinases Leukemia Lung cancer Lung diseases Lung Neoplasms - genetics Lung Neoplasms - metabolism Medicine Mutation Non-small cell lung cancer Non-small cell lung carcinoma Phagocytosis Pharmacology Protein-tyrosine kinase Proteins Quinazolines - pharmacology Rapamycin Regulatory proteins Ribonucleic acid RNA RNA Interference siRNA Targeted cancer therapy TOR protein TOR Serine-Threonine Kinases - metabolism Transfection Translation Tumorigenesis Tumors Tyrosine Ubiquitin-Conjugating Enzymes - genetics Ubiquitin-Conjugating Enzymes - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!